Global Pharmaceuticals: China's Rising Influence and Weight-Loss Drug Dynamics
This collection of Financial Times articles from late 2025 to April 2026 highlights significant shifts in the global pharmaceutical industry, with a particular focus on China's emerging dominance and the evolving landscape of weight-loss treatments. China is positioned to drive a price war in GLP-1 drugs as semaglutide patents expire, leveraging its capacity for scaled production. Simultaneously, Chinese biotech firms like Hansoh Pharma are achieving promising clinical results in oncology, attracting major licensing deals from Western giants such as GSK and Merck. The sector sees substantial M&A activity, including Merck's $5.7 billion acquisition of Terns Pharma, aimed at bolstering cancer pipelines. Meanwhile, the obesity drug market remains volatile, with Novo Nordisk and Eli Lilly reporting mixed trial outcomes, regulatory warnings about side effects like pancreatitis, and concerns over long-term weight regain. Broader trends include EU regulatory changes shortening drug exclusivity periods, debates over statin side effect labeling, and the rise of untested wellness peptides. The narrative underscores a strategic pivot where Western multinationals increasingly rely on Chinese innovation for cost-effective development and new therapeutic breakthroughs.
Wire timeline
Global Pharmaceuticals: China's Rising Influence and Weight-Loss Drug Dynamics
This collection of Financial Times articles from late 2025 to April 2026 highlights significant shifts in the global pharmaceutical industry, with a particular focus on China's emerging dominance and the evolving landscape of weight-loss treatments. China is positioned to drive a price war in GLP-1 drugs as semaglutide patents expire, leveraging its capacity for scaled production. Simultaneously, Chinese biotech firms like Hansoh Pharma are achieving promising clinical results in oncology, attracting major licensing deals from Western giants such as GSK and Merck. The sector sees substantial M&A activity, including Merck's $5.7 billion acquisition of Terns Pharma, aimed at bolstering cancer pipelines. Meanwhile, the obesity drug market remains volatile, with Novo Nordisk and Eli Lilly reporting mixed trial outcomes, regulatory warnings about side effects like pancreatitis, and concerns over long-term weight regain. Broader trends include EU regulatory changes shortening drug exclusivity periods, debates over statin side effect labeling, and the rise of untested wellness peptides. The narrative underscores a strategic pivot where Western multinationals increasingly rely on Chinese innovation for cost-effective development and new therapeutic breakthroughs.
ft